GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoveren Scientific Inc (OTCPK:IVRN) » Definitions » EV-to-Revenue

Innoveren Scientific (Innoveren Scientific) EV-to-Revenue : (As of May. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Innoveren Scientific EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Innoveren Scientific's enterprise value is $4.34 Mil. Innoveren Scientific's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Therefore, Innoveren Scientific's EV-to-Revenue for today is .

The historical rank and industry rank for Innoveren Scientific's EV-to-Revenue or its related term are showing as below:

IVRN' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.99   Med: 8.48   Max: 702.67
Current: 9.57

During the past 10 years, the highest EV-to-Revenue of Innoveren Scientific was 702.67. The lowest was 0.99. And the median was 8.48.

IVRN's EV-to-Revenue is ranked worse than
53.88% of 1043 companies
in the Biotechnology industry
Industry Median: 8.21 vs IVRN: 9.57

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Innoveren Scientific's stock price is $0.0055. Innoveren Scientific's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Therefore, Innoveren Scientific's PS Ratio for today is .


Innoveren Scientific EV-to-Revenue Historical Data

The historical data trend for Innoveren Scientific's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoveren Scientific EV-to-Revenue Chart

Innoveren Scientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.73 2.41 1.00 8.29 13.22

Innoveren Scientific Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.23 13.22 120.67 - -

Competitive Comparison of Innoveren Scientific's EV-to-Revenue

For the Biotechnology subindustry, Innoveren Scientific's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoveren Scientific's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoveren Scientific's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Innoveren Scientific's EV-to-Revenue falls into.



Innoveren Scientific EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Innoveren Scientific's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=4.337/0
=

Innoveren Scientific's current Enterprise Value is $4.34 Mil.
Innoveren Scientific's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innoveren Scientific  (OTCPK:IVRN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Innoveren Scientific's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0055/0
=

Innoveren Scientific's share price for today is $0.0055.
Innoveren Scientific's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innoveren Scientific EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Innoveren Scientific's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoveren Scientific (Innoveren Scientific) Business Description

Traded in Other Exchanges
N/A
Address
2202 N West Shore Boulevard, Suite 200, Tampa, FL, USA, 33607
Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.
Executives
Fwhc Holdings, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Hoa Capital Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Farrior J Rex Iii 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Fwhc Bridge Friends, Llc 10 percent owner 1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Raymond Monteleone director 201 E KENNEDY BLVD, STE 700, TAMPA FL 33602
Jeremy Daniel officer: Chief Financial Officer 201 E KENNEDY AVE, STE 700, TAMPA FL 33602
Robert Smith Greif officer: President and C.E.O. 19 MAY STREET, NEEDHAM MA 02492
Cfrs Investments, Llc 10 percent owner 2903 W VILLA ROSA PARK, TAMPA FL 33611
Frederick J Lynch 10 percent owner C/O MASONITE INTERNATIONAL CORPORATION, 201 NORTH FRANKLIN ST., SUITE 300, TAMPA FL 33602
Fwhc Bridge, Llc 10 percent owner 334 EAST LAKE ROAD, SUITE 176, PALM HARBOT FL 34685
Todd R Wagner 10 percent owner 3385 OLD KEYSTONE ROAD, TARPON SPRINGS FL 34688
Michael Yurkowsky director 2380 OLD MILTON PARKWAY, ALPHARETTA GA 30009
William E Horne director, officer: Chief Executive Officer 201 EAST KENNEDY BLVD, SUITE 700, TAMPA FL 33602
Jon Mogford director 714 PLUM HOLLOW DRIVE, COLLEGE STATION TX 77845
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615

Innoveren Scientific (Innoveren Scientific) Headlines

From GuruFocus

H-CYTE Announces 1-for-1,000 Reverse Stock Split

By PurpleRose PurpleRose 07-14-2022

H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise

By GuruFocusNews GuruFocusNews 03-04-2022

H-CYTE Names Michael Yurkowsky Chief Executive Officer

By GuruFocusNews GuruFocusNews 12-06-2021

Medovex Corporation Announces Recent Management Appointments

By Marketwired Marketwired 04-29-2019

Medovex Corporation Announces New Board Appointments

By Marketwired Marketwired 01-15-2019

H-CYTE Issues Letter to Shareholders

By Marketwired Marketwired 01-21-2020